your market intelligence analyst
Search Results
141 results
Your search is now limited to «Celgene» expert search.
PR Newswire 11/13/2019 15:30
Today's announcement marks the third opt-in executed by Celgene since the companies announced a collaboration focused on hematological malignancies in June 2017 , and follows on Dragonfly's December 2018 announcement of Celgene's opt-in for the first two TriNKET™ immunotherapy drug candidates.
More from PR Newswire:
NASDAQ 11/13/2019 10:00
Along with the earnings release, Editas announced an amended agreement with Celgene to focus on engineered alpha-beta T cell medicines.
More from NASDAQ:
Motley Fool 11/13/2019 09:00
With first patient dosing for EDIT-101 drawing near, Editas is powering forward with other promising medicines and partnerships.
More from Motley Fool:
ENDPOINTS 11/12/2019 10:44
Editas Medicine is amending its long-running collaboration with Celgene and their subsidiary Juno Therapeutics.
More from ENDPOINTS:
Business Wire 11/12/2019 06:59
... participation date of May 1, 2019, requisite consents were received and supplemental indentures were executed, eliminating substantially all restrictive covenants and certain events of default and other provisions in each of the indentures governing the Celgene Notes.
More from Business Wire:
Xconomy 11/08/2019 16:22
A drug that Celgene and Acceleron Pharma developed to treat low red blood cell levels in patients who have a rare blood disorder now has regulatory clearance to enter the market.
More from Xconomy:
FiercePharmaManufacturing 11/08/2019 16:09
RELATED: In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful With two of those "big 5" now approved, Bristol and Celgene will look to three late-stage candidates to give investors more hope for the merger.
More from FiercePharmaManufacturing:
Channel NewsAsia (Singapore) 11/08/2019 15:40
The drug was jointly developed by Acceleron and Celgene, which is being bought by Bristol-Myers Squibb Co. A typical dose of Reblozyl consists of 1 mg of the drug for a kilogram of patient's weight.
More from Channel NewsAsia (Singapore):
BioPharma Dive 11/07/2019 11:54
Mark this year's American Society of Hematology meeting as one of the last times the biopharma community sees Celgene as an independent company.
More from BioPharma Dive:
(MENAFN - The Expresswire) What's driving the Gene Therapy Market Growth? Prominent Players: Pfizer, Novartis, Bayer, Sanofi, GSK, Amgen, Boehringer Ingelheim International GmbH, u...
More from Middle East North Africa Financial Network (MENAFN):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications